Verily
The industry is better off viewing the the floundering deals between Onduo and Sanofi, Proteus and Otsuka, and Pear and Sandoz as a learning opportunity.
From its acquisition of Fitbit to Project Nightingale, 2019 has been eventful for Alphabet and its subsidiaries.
New CEO Paul Hudson said during today's strategy presentation that the company had "over-invested" in the joint venture back in 2016.
All of the life insurer’s members with Type 1 or Type 2 diabetes will have access to the service, which offers savings on premiums.
The pair will be targeting patients with asymptomatic or silent atrial fibrillation.
Also: RenalytixAI taps Thoma McLain as new CCO; Luba Greenwood announces departure from Verily.
MassBio's Luba Greenwood also discusses her decision to leave Verily in order to pursue teaching the intersection of life science and technology at Harvard.
Pharma companies also continued to explore the promises of digital therapeutics.
This morning MassBio hosted a panel on the use cases for the technology in clinical trials and beyond.
The pharmas will be employing Verily's Project Baseline platform to streamline recruitment and data collection during clinical research.